ACTION-1试验中[225Ac]Ac-DOTATATE在GEP-NET患者中的剂量学结果
ACTION-1是一项1b/3期随机对照开放标签试验,纳入SSTR表达、分化良好、177Lu-SSA治疗后进展的GEP-NET患者,通过SPECT/CT显像221Fr和213Bi进行[225Ac]Ac-DOTATATE的剂量学评估。1b期17例中9例完成4周期并获得剂量学数据,肾脏和红骨髓吸收剂量分别为22.3 Gy和1.1 Gy,所选肿瘤的ADCRBE=5范围为488至8775 mGy/MBq。结论认为基于图像的225Ac剂量学可行,肿瘤/正常组织吸收剂量比有利。
要点
- 9例完成4周期[225Ac]Ac-DOTATATE治疗的患者获得剂量学数据。
- 肾脏和红骨髓吸收剂量分别为22.3 Gy和1.1 Gy。
- 所选肿瘤ADCRBE=5范围为488至8775 mGy/MBq。
核心结论
- ACTION-1剂量学数据表明通过SPECT/CT显像221Fr和213Bi实现225Ac的基于图像的剂量学是可行的。
- 213Bi子体大部分与DOTATATE共同留在肿瘤中,与221Fr在同一位置衰变。
- [225Ac]Ac-DOTATATE有利的肿瘤/正常组织吸收剂量比支持其在SSTR表达GEP-NET患者中的应用。
研究设计与样本
- ACTION-1(NCT05477576)是一项2部分、随机、对照、开放标签的1b/3期试验。
- 纳入成人1级或2级、分化良好、不可手术、SSTR2表达、177Lu标记SSA治疗2-4周期后进展的GEP-NET患者。
- [225Ac]Ac-DOTATATE每8周静脉给药1-4周期,在第1和4周期后通过SPECT/CT显像221Fr和213Bi进行剂量学评估。
- 计算经相对生物效应因子5调整的吸收剂量和吸收剂量系数(ADCRBE=5),肿瘤剂量采用MIRD S值方法估算。
主要发现
- 1b期17例患者中9例获得剂量学数据,每例完成4周期。
- 213Bi大部分与DOTATATE共同留在肿瘤中,少部分进入肾脏。
- 肾脏和红骨髓估计吸收剂量分别为22.3 Gy和1.1 Gy。
- 两个治疗周期中所选肿瘤的ADCRBE=5范围为488至8775 mGy/MBq。
- 大多数肿瘤第4周期ADCRBE=5低于第1周期,第1周期定义的许多肿瘤在第4周期无法识别。
关键数值与推荐
- 肾脏估计吸收剂量为22.3 Gy,红骨髓为1.1 Gy。
- 所选肿瘤ADCRBE=5在两个治疗周期中范围为488至8775 mGy/MBq。
临床怎么用
- 可利用SPECT/CT显像221Fr和213Bi对[225Ac]Ac-DOTATATE进行基于图像的剂量学评估。
- 剂量学结果提示[225Ac]Ac-DOTATATE在SSTR表达GEP-NET患者中具有有利的肿瘤/正常组织吸收剂量比。
局限性
- 剂量学数据仅来自1b期17例患者中的9例。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are biologically and clinically heterogeneous tumors, most of which overexpress somatostatin receptors (SSTRs). The presence of SSTRs enables staging and allows patient selection for treatment with radiolabeled somatostatin analogs (SSAs), such as DOTATATE. [225Ac]Ac-DOTATATE is an α-emitting radiopharmaceutical in development for the treatment of patients with SSTR2-expressing solid tumors. α particles have a shorter path length and higher linear energy transfer than do β particles, leading to largely irreparable double-strand DNA breaks and cytotoxicity. ACTION-1 (NCT05477576) is a 2-part, randomized, controlled, open-label, phase 1b/3 trial of [225Ac]Ac-DOTATATE in patients with SSTR-expressing GEP-NETs whose disease progressed after 177Lu-labeled SSA therapy. ACTION-1 included a dosimetry substudy to determine the feasibility of obtaining imaging data with 225Ac. The objectives of the substudy were to estimate radiation absorbed doses of [225Ac]Ac-DOTATATE in critical organs and tumors. Methods: [225Ac]Ac-DOTATATE was administered intravenously every 8 wk for 1-4 cycles to adults with grade 1 or 2, well-differentiated, inoperable SSTR2-expressing GEP-NETs that progressed after 2-4 cycles of 177Lu-lableled SSA. Dosimetry was assessed after cycles 1 and 4 of [225Ac]Ac-DOTATATE via SPECT/CT of 221Fr (4.8-min half-life), the first daughter and surrogate for 225Ac and 213Bi (46.6-min half-life, surrogate for later daughters). Absorbed doses and absorbed dose coefficients adjusted for a relative biological effectiveness factor of 5 (ADCRBE=5) to target tissues and tumors were calculated; tumor doses were estimated by MIRD S-value methodology. Results: Dosimetry data were obtained from 9 of 17 patients in phase 1b, each completing 4 cycles. 213Bi mostly remained with DOTATATE in the tumors; a minor fraction went to the kidneys. The estimated absorbed doses to kidneys and red bone marrow were 22.3 and 1.1 Gy, respectively. The ADCRBE=5 to selected tumors ranged from 488 to 8775 mGy/MBq across both treatment cycles. The ADCRBE=5 for most tumors was lower in cycle 4 than in cycle 1; many tumors defined in cycle 1 were unidentifiable in cycle 4. Conclusion: Dosimetry data from ACTION-1 demonstrated the feasibility of image-based dosimetry of 225Ac through SPECT/CT imaging of 221Fr and 213Bi. The 213Bi daughter mostly remained with DOTATATE in tumors, decaying at the same location as 221Fr. The favorable tumor-to-normal tissue absorbed dose ratio of [225Ac]Ac-DOTATATE supports its use in patients with SSTR-expressing GEP-NETs.
引用
- Sgouros G, Ulaner GA, He B, et al. Dosimetry Results from the Phase 1b/3 ACTION-1 Trial of [225Ac]Ac-DOTATATE (RYZ101) in Patients with Somatostatin Receptor-Expressing, Well-Differentiated GEP-NETs. J Nucl Med. 2026. PMID: 42242867. doi:10.2967/jnumed.125.270573
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。